Skip to main content
eScholarship
Open Access Publications from the University of California

Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: A randomized, double-blind, placebo-controlled clinical trial

  • Author(s): Jacobson, JM
  • Routy, JP
  • Welles, S
  • DeBenedette, M
  • Tcherepanova, I
  • Angel, JB
  • Asmuth, DM
  • Stein, DK
  • Baril, JG
  • McKellar, M
  • Margolis, DM
  • Trottier, B
  • Wood, K
  • Nicolette, C
  • et al.
Abstract

© Copyright 2015 Wolters Kluwer Health, Inc. All rights reserved. Background: The genomic heterogeneity of HIV-1 impedes the ability of consensus sequences in vaccines to elicit effective antiviral immune responses. AGS-004 amplifies translation-competent RNA molecules encoding for Gag, Rev, Vpr, and Nef from the patient's autologous virus and loads them into dendritic cells. Methods: This phase IIB, multicenter, 2:1 randomized, doubleblind, placebo-controlled study enrolled 54 HIV-1-infected patients on antiretroviral therapy with viral loads (VLs) <50 copies per milliliter, current CD4 T-cell counts >450 cells per cubic millimeter, and nadir counts >200 cells per cubic millimeter, to receive intradermal injections of study product into the axillary lymph node region every 4 weeks. At week 16, a 12-week analytical treatment interruption (ATI) was undertaken. Results: There was no difference in the end-of-ATI VL (average of values from weeks 11 and 12) between the 2 arms of the study [4.39 (4.17, 4.69) vs. 4.47 (3.76, 4.64) log10 HIV-1 RNA; P = 0.73]. Between arms, no change between pre-antiretroviral therapy VL and the end-of-ATI VL [20.06 (0.24, 20.32) vs. 20.17 (0.17, 20.32) log10 HIV-1 RNA; P = 0.43] was observed. When interferon-g, interleukin-2, tumor necrosis factor a, CD107a, and granzyme b expressions were measured by multicolor flow cytometry, a greater percentage of AGS-004 than of placebo recipients had multifunctional cytotoxic T-lymphocyte responses induced in the CD28 +/CD45RA-CD8 effector/memory T-cell population to dendritic cells electroporated with autologous antigens. Adverse events consisted of transient, mild (grade 1) local injection site reactions. Conclusions: Despite the induction of HIV-specific effector/ memory CD8 T-cell responses, no antiviral effect was seen after the administration of AGS-004 when compared with placebo.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View